Vinay Badhwar1, J Scott Rankin2, Ralph J Damiano3, A Marc Gillinov4, Faisal G Bakaeen4, James R Edgerton5, Jonathan M Philpott6, Patrick M McCarthy7, Steven F Bolling8, Harold G Roberts9, Vinod H Thourani10, Rakesh M Suri4, Richard J Shemin11, Scott Firestone12, Niv Ad2. 1. Division of Cardiothoracic Surgery, West Virginia University, Morgantown, West Virginia. Electronic address: vinay.badhwar@wvumedicine.org. 2. Division of Cardiothoracic Surgery, West Virginia University, Morgantown, West Virginia. 3. Division of Cardiothoracic Surgery, Washington University, St. Louis, Missouri. 4. Division of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. 5. Department of Cardiothoracic Surgery, Baylor Plano Heart Hospital, Plano, Texas. 6. Department of Cardiothoracic Surgery, Sentara Heart Hospital, Norfolk, Virginia. 7. Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 8. Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan. 9. Department of Cardiovascular Services, Florida Heart and Vascular Care at Aventura, Aventura, Florida. 10. Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia. 11. Division of Cardiothoracic Surgery, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California. 12. The Society of Thoracic Surgeons, Chicago, Illinois.
Abstract
EXECUTIVE SUMMARY: Surgical ablation for atrial fibrillation (AF) can be performed without additional risk of operative mortality or major morbidity, and is recommended at the time of concomitant mitral operations to restore sinus rhythm. (Class I, Level A) Surgical ablation for AF can be performed without additional operative risk of mortality or major morbidity, and is recommended at the time of concomitant isolated aortic valve replacement, isolated coronary artery bypass graft surgery, and aortic valve replacement plus coronary artery bypass graft operations to restore sinus rhythm. (Class I, Level B nonrandomized) Surgical ablation for symptomatic AF in the absence of structural heart disease that is refractory to class I/III antiarrhythmic drugs or catheter-based therapy or both is reasonable as a primary stand-alone procedure, to restore sinus rhythm. (Class IIA, Level B randomized) Surgical ablation for symptomatic persistent or longstanding persistent AF in the absence of structural heart disease is reasonable, as a stand-alone procedure using the Cox-Maze III/IV lesion set compared with pulmonary vein isolation alone. (Class IIA, Level B nonrandomized) Surgical ablation for symptomatic AF in the setting of left atrial enlargement (≥4.5 cm) or more than moderate mitral regurgitation by pulmonary vein isolation alone is not recommended. (Class III no benefit, Level C expert opinion) It is reasonable to perform left atrial appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C limited data) At the time of concomitant cardiac operations in patients with AF, it is reasonable to surgically manage the left atrial appendage for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C expert opinion) In the treatment of AF, multidisciplinary heart team assessment, treatment planning, and long-term follow-up can be useful and beneficial to optimize patient outcomes. (Class I, Level C expert opinion).
EXECUTIVE SUMMARY: Surgical ablation for atrial fibrillation (AF) can be performed without additional risk of operative mortality or major morbidity, and is recommended at the time of concomitant mitral operations to restore sinus rhythm. (Class I, Level A) Surgical ablation for AF can be performed without additional operative risk of mortality or major morbidity, and is recommended at the time of concomitant isolated aortic valve replacement, isolated coronary artery bypass graft surgery, and aortic valve replacement plus coronary artery bypass graft operations to restore sinus rhythm. (Class I, Level B nonrandomized) Surgical ablation for symptomatic AF in the absence of structural heart disease that is refractory to class I/III antiarrhythmic drugs or catheter-based therapy or both is reasonable as a primary stand-alone procedure, to restore sinus rhythm. (Class IIA, Level B randomized) Surgical ablation for symptomatic persistent or longstanding persistent AF in the absence of structural heart disease is reasonable, as a stand-alone procedure using the Cox-Maze III/IV lesion set compared with pulmonary vein isolation alone. (Class IIA, Level B nonrandomized) Surgical ablation for symptomatic AF in the setting of left atrial enlargement (≥4.5 cm) or more than moderate mitral regurgitation by pulmonary vein isolation alone is not recommended. (Class III no benefit, Level C expert opinion) It is reasonable to perform left atrial appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C limited data) At the time of concomitant cardiac operations in patients with AF, it is reasonable to surgically manage the left atrial appendage for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C expert opinion) In the treatment of AF, multidisciplinary heart team assessment, treatment planning, and long-term follow-up can be useful and beneficial to optimize patient outcomes. (Class I, Level C expert opinion).
Authors: Ali J Khiabani; Taylan Adademir; Richard B Schuessler; Spencer J Melby; Marc R Moon; Ralph J Damiano Journal: Innovations (Phila) Date: 2018 Nov/Dec
Authors: Chawannuch Ruaengsri; Matthew R Schill; Ali J Khiabani; Richard B Schuessler; Spencer J Melby; Ralph J Damiano Journal: Eur J Cardiothorac Surg Date: 2018-04-01 Impact factor: 4.191
Authors: Eugene H Blackstone; Helena L Chang; Jeevanantham Rajeswaran; Michael K Parides; Hemant Ishwaran; Liang Li; John Ehrlinger; Annetine C Gelijns; Alan J Moskowitz; Michael Argenziano; Joseph J DeRose; Jean-Phillipe Couderc; Dan Balda; François Dagenais; Michael J Mack; Gorav Ailawadi; Peter K Smith; Michael A Acker; Patrick T O'Gara; A Marc Gillinov Journal: J Thorac Cardiovasc Surg Date: 2018-07-27 Impact factor: 5.209
Authors: Daniel O Johnsrud; Rowlens M Melduni; Brian Lahr; Xiaoxi Yao; Kevin L Greason; Peter A Noseworthy Journal: Clin Cardiol Date: 2018-12-10 Impact factor: 2.882